Bellicum Pharmaceuticals to Participate in Two Healthcare Investor Conferences in September
Conference Details:
Event: Citi’s 13th Annual
Date: Wednesday, September 5, 2018
Location: Boston, MA
Event: 2018
Date/Time: Thursday, September 6, 2018 at 10:55 a.m. EDT
Location: Boston, MA
A live webcast of the presentation at
About
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
Source:
Investors: Solebury TroutChad Rubin 646-378-2947 crubin@soleburytrout.com Media: Solebury TroutBrad Miles 646-513-3125 bmiles@troutgroup.com
Source: Bellicum Pharmaceuticals, Inc.